Group: Non-Oncological Applications
DNA Vaccination by Electroporation
This heading gathers records in which DNA vaccines against infectious disease are delivered by electroporation. Electroporation here is not a treatment but a delivery method that moves plasmid DNA into muscle or skin cells. The records cover vaccine candidates against hantavirus (HFRS), Crimean-Congo haemorrhagic fever, respiratory syncytial virus and SARS-CoV-2; most are animal studies, and one is a phase 2a randomized immunogenicity trial in humans. The area falls outside the oncological scope of the portal and does not appear in the indication directory; it is kept in the corpus to show where the same delivery method is being tested outside oncology. The number of publications here does not indicate that a vaccine is approved or in use.
Clinical publications: randomized, prospective and retrospective studies, case series and case reports. Preclinical publications: animal, in vitro, modelling and experimental biophysics studies.
Clinical and Technical Data Reported in the Publications
The sum of the fields reported in the full text of the 8 publications in this area. The numbers are summed, not interpreted.
The totals are not a count of unique patients: the same cohort may have been reported in more than one publication.
Literature Status by Method
Publication count, clinical and preclinical split, literature volume and publication span for each clinical method. The badges at the top of the page summarise the Other EP and Gene ET records separately; the full split by method is here.
Gene electrotransfer
Exploratory / low-volume literaturethreshold 0/1 records
No record for this method feeds the volume label.
2023–2023
Other electroporation applications
This set does not name a single clinical method; no literature volume is assigned.
2006–2023
Mechanisms Mentioned in Abstracts
The figure is the number of abstracts mentioning the mechanism. A mention does not mean it was demonstrated in that study.
Study Type Distribution
The percentage gives the share of the whole area.
| Study type | Publications | Share within this area |
|---|---|---|
| Randomized Clinical Trial | 1 | 12% |
| Animal Study | 7 | 88% |
Publication Table
8 publication records sorted by study design. Click a title to open the citation, mechanism and full abstract drawer.
Classifications are generated automatically and can be wrong for individual records. Methodology
| Regime | Publication | Year | Study type | Model | Mechanism | Patients / lesions | Device | Agent and route | Reported outcome | Abstract |
|---|---|---|---|---|---|---|---|---|---|---|
| Other EP | Hooper et al · Vaccines (Basel) | 2020 | Randomized Clinical Trial | Human | Gene Electrotransfer (Plasmid DNA), Haemostasis and Bleeding Control | 130 | TDS-IM, TriGrid Intramuscular Delivery System | plasmid DNA · other route | overall survival 90.8% (120 patients) | Hantaan virus (HTNV) and Puumala virus (PUUV) are pathogenic hantaviruses found in Asia and Europe, respectively. DNA vaccines targeting the envelope glycoproteins of these viruses have been… |
| Gene ET | Kamensek · Pharmaceutics | 2023 | Animal Study | Animal (In Vivo) | Gene Electrotransfer (Plasmid DNA), Interleukin-12 Mediated Immune Stimulation | – | Cliniporator, IGEA electric pulse generator | plasmid DNA · intratumoural | – | DNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious diseases and therapeutic vaccination against cancer.… |
| Other EP | Martins et al · Arch Virol | 2023 | Animal Study | Animal (In Vivo) | Gene Electrotransfer (Plasmid DNA) | – | Vet-ePorator™ | plasmid DNA · intratumoural | – | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has caused more than 760 million cases and over 6.8 million deaths a… |
| Other EP | Xia et al · Proc Natl Acad Sci U S A | 2021 | Animal Study | Animal (In Vivo) | Electrode Geometry and Placement, Gene Electrotransfer (Plasmid DNA) | – | ePatch, BTX Electro Cell Manipulator 600 | plasmid DNA · intratumoural | – | Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other pathogens with pandemic potential requires safe, protective, inexpensive, and easily accessible vac… |
| Other EP | Hawman et al · Nat Microbiol | 2020 | Animal Study | Animal (In Vivo) | Haemostasis and Bleeding Control | – | Genedrive | plasmid DNA · intravenous | – | There is currently no specific prophylaxis or vaccine against Crimean-Congo haemorrhagic fever virus (CCHFV). Crimean-Congo haemorrhagic fever (CCHF) is a severe febrile illness transmitted … |
| Other EP | Grunwald et al · J Virol | 2014 | Animal Study | Animal (In Vivo) | Systemic / Abscopal Immune Response, Gene Electrotransfer (Plasmid DNA) | – | TriGrid delivery system, Cliniporator | plasmid DNA · other route | – | Unlabelled: Induction of long-lasting immunity against viral respiratory tract infections remains an elusive goal. Using a nonhuman primate model of human respiratory syncytial virus (hRSV) … |
| Other EP | Vasan et al · Retrovirology | 2009 | Animal Study | Animal (In Vivo) | – | 40 | TriGrid Delivery System | plasmid DNA · intravenous | – | In healthy volunteers, we sought to determine the safety, tolerability, and immunogenicity of ADVAX, a subtype B'/C, DNA-based, multigenic, HIV-1 vaccine candidate, when injected intramuscul… |
| Other EP | Hirao et al · Molecular Therapy | 2006 | Animal Study | Animal (In Vivo) | Gene Electrotransfer (Plasmid DNA) | – | ADViSYS constant-current EKD system | plasmid DNA · intratumoural | – | Although DNA vaccines have proven to be highly immunogenic in small animal models, the same level of immunogenicity has yet to be seen in non-human primate models and more importantly in hum… |
Limitations
Publication volume is not clinical efficacy or evidence quality. It describes how much literature exists in the area and of what kind; it does not indicate how strongly the treatment is supported, guideline endorsement or regulatory status.
Patient totals are not a count of unique patients. The same cohort may have been reported in more than one publication; the totals are not a meta-analysis.
How the corpus was assembled, the tier thresholds, the definition of a clinical publication and why methods are counted separately: Literature Map.